Thyroid hormone analogues and derivatives: Actions in fatty liver

World Journal of Hepatology

Volumn 6, Issue 3, 2014, Pages 114-129

  Coppola, Maria ^a   Glinni, Daniela ^a   Moreno, Maria ^a   Cioffi, Federica ^a   Silvestri, Elena ^a   Goglia, Fernando ^a  

^a UNIVERSITY OF SANNIO   (Italy)

Author keywords

3,5 diiodo L thyronine; Fatty liver; Lipid metabolism; Thyroid hormones; Thyromimetics

Indexed keywords

EID: 84907738394     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v6.i3.114     Document Type: Article

References (138)

1. Ibrahim MA, Kelleni M, Geddawy A. Nonalcoholic fatty liver disease: current and potential therapies. Life Sci 2013; 92: 114-118 [PMID: 23159641 DOI: 10.1016/j.lfs.2012.11.004]
2. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114: 147-152 [PMID: 15254578]
3. Bradbury MW, Berk PD. Lipid metabolism in hepatic steatosis. Clin Liver Dis 2004; 8: 639-71, xi [PMID: 15331068]
4. Postic C, Girard J. The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes Metab 2008; 34: 643-648 [PMID: 19195625 DOI: 10.1016/S1262-3636(08)74599-3]
5. Pessayre D. Role of mitochondria in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2007; 22 Suppl 1: S20-S27 [PMID: 17567459]
6. Serviddio G, Sastre J, Bellanti F, Viña J, Vendemiale G, Altomare E. Mitochondrial involvement in non-alcoholic steatohepatitis. Mol Aspects Med 2008; 29: 22-35 [PMID: 18061659]
7. Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S, Miyazaki Y, Kohane I, Costello M, Saccone R, Landaker EJ, Goldfine AB, Mun E, DeFronzo R, Finlayson J, Kahn CR, Mandarino LJ. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci USA 2003; 100: 8466-8471 [PMID: 12832613]
8. Sparks LM, Xie H, Koza RA, Mynatt R, Hulver MW, Bray GA, Smith SR. A high-fat diet coordinately downregulates genes required for mitochondrial oxidative phosphorylation in skeletal muscle. Diabetes 2005; 54: 1926-1933 [PMID: 15983191]
9. Lomonaco R, Sunny NE, Bril F, Cusi K. Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs 2013; 73: 1-14 [PMID: 23329465 DOI: 10.1007/ s40265-012-0004-0]
10. Tessari P, Coracina A, Cosma A, Tiengo A. Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2009; 19: 291-302 [PMID: 19359149 DOI: 10.1016/j.numecd.2008.12.015]
11. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006; 40 Suppl 1: S17-S29 [PMID: 16540762]
12. Videla LA, Rodrigo R, Araya J, Poniachik J. Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Radic Biol Med 2004; 37: 1499-1507 [PMID: 15454290]
13. Sies H, Stahl W, Sevanian A. Nutritional, dietary and postprandial oxidative stress. J Nutr 2005; 135: 969-972 [PMID: 15867266]
14. Aronis A, Madar Z, Tirosh O. Mechanism underlying oxidative stress-mediated lipotoxicity: exposure of J774.2 macrophages to triacylglycerols facilitates mitochondrial reactive oxygen species production and cellular necrosis. Free Radic Biol Med 2005; 38: 1221-1230 [PMID: 15808420]
15. Méndez-Sánchez N, Arrese M, Zamora-Valdés D, Uribe M. Treating nonalcoholic fatty liver disease. Liver Int 2007; 27: 1157-1165 [PMID: 17919226]
16. Oh MK, Winn J, Poordad F. Review article: diagnosis and treatment of non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 28: 503-522 [PMID: 18532991 DOI: 10.1111/ j.1365-2036.2008.03752.x]
17. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-2307 [PMID: 17135584]
18. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, Austin AS, Freeman JG, Morgan L, Webber J. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008; 135: 1176-1184 [PMID: 18718471 DOI:10.1053/j.gastro.2008.06.047]
19. Pramfalk C, Pedrelli M, Parini P. Role of thyroid receptor β in lipid metabolism. Biochim Biophys Acta 2011; 1812: 929-937 [PMID: 21194564 DOI: 10.1016/j.bbadis.2010.12.019]
20. Perra A, Simbula G, Simbula M, Pibiri M, Kowalik MA, Sulas P, Cocco MT, Ledda-Columbano GM, Columbano A. Thyroid hormone (T3) and TRbeta agonist GC-1 inhibit/ reverse nonalcoholic fatty liver in rats. FASEB J 2008; 22: 2981-2989 [PMID: 18434432 DOI: 10.1096/fj.08-108464]
21. Braverman LE, Utiger RD. Introduction to thyrotoxicosis. Werner and Ingbar, editors. Lippincott: The Thyroid, 2000: 515-517
22. Moreno M, de Lange P, Lombardi A, Silvestri E, Lanni A, Goglia F. Metabolic effects of thyroid hormone derivatives. Thyroid 2008; 18: 239-253 [PMID: 18279024 DOI: 10.1089/ thy.2007.0248]
23. Baxter JD, Webb P. Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov 2009; 8: 308-320 [PMID: 19337272 DOI: 10.1038/nrd2830]
24. Davis PJ, Lin HY, Mousa SA, Luidens MK, Hercbergs AA, Wehling M, Davis FB. Overlapping nongenomic and genomic actions of thyroid hormone and steroids. Steroids 2011; 76: 829-833 [PMID: 21354437 DOI: 10.1016/ j.steroids.2011.02.012]
25. Lanni A, Moreno M, Lombardi A, de Lange P, Goglia F. Control of energy metabolism by iodothyronines. J Endocrinol Invest 2001; 24: 897-913 [PMID: 11817716]
26. Goglia F. Biological effects of 3,5-diiodothyronine (T(2)). Biochemistry (Mosc) 2005; 70: 164-172 [PMID: 15807655]
27. Bassett JH, Harvey CB, Williams GR. Mechanisms of thyroid hormone receptor-specific nuclear and extra nuclear actions. Mol Cell Endocrinol 2003; 213: 1-11 [PMID: 15062569]
28. Lazar MA. Thyroid hormone action: a binding contract. J Clin Invest 2003; 112: 497-499 [PMID: 12925689]
29. Moeller LC, Broecker-Preuss M. Transcriptional regulation by nonclassical action of thyroid hormone. Thyroid Res 2011; Suppl 1: S6 [PMID: 21835053 DOI: 10.1186/1756-6614-4-S1 -S6]
30. Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr Rev 2010; 31: 139-170 [PMID: 20051527 DOI: 10.1210/er.2009-0007]
31. Pihlajamäki J, Boes T, Kim EY, Dearie F, Kim BW, Schroeder J, Mun E, Nasser I, Park PJ, Bianco AC, Goldfine AB, Patti ME. Thyroid hormone-related regulation of gene expression in human fatty liver. J Clin Endocrinol Metab 2009; 94: 3521-3529 [PMID: 19549744 DOI: 10.1210/jc.2009-0212]
32. Chou WY, Cheng YS, Ho CL, Liu ST, Liu PY, Kuo CC, Chang HP, Chen YH, Chang GG, Huang SM. Human spot protein interacts physically and functionally with the thyroid receptor. Biochem Biophys Res Commun 2007; 357: 133-138 [PMID: 17418816]
33. Flores-Morales A, Gullberg H, Fernandez L, Ståhlberg N, Lee NH, Vennström B, Norstedt G. Patterns of liver gene expression governed by TRbeta. Mol Endocrinol 2002; 16: 1257-1268 [PMID: 12040013]
34. Hashimoto K, Yamada M, Matsumoto S, Monden T, Satoh T, Mori M. Mouse sterol response element binding protein-1c gene expression is negatively regulated by thyroid hormone. Endocrinology 2006; 147: 4292-4302 [PMID: 16794015]
35. Jackson-Hayes L, Song S, Lavrentyev EN, Jansen MS, Hillgartner FB, Tian L, Wood PA, Cook GA, Park EA. A thyroid hormone response unit formed between the promoter and first intron of the carnitine palmitoyltransferase-Ialpha gene mediates the liver-specific induction by thyroid hormone. J Biol Chem 2003; 278: 7964-7972 [PMID: 12493735]
36. Oetting A, Yen PM. New insights into thyroid hormone action. Best Pract Res Clin Endocrinol Metab 2007; 21: 193-208 [PMID: 17574003]
37. Rodgers JT, Puigserver P. Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. Proc Natl Acad Sci USA 2007; 104: 12861-12866 [PMID: 17646659]
38. Feige JN, Auwerx J. Transcriptional coregulators in the control of energy homeostasis. Trends Cell Biol 2007; 17: 292-301 [PMID: 17475497]
39. Thakran S, Sharma P, Attia RR, Hori RT, Deng X, Elam MB, Park EA. Role of sirtuin 1 in the regulation of hepatic gene expression by thyroid hormone. J Biol Chem 2013; 288: 807-818 [PMID: 23209300 DOI: 10.1074/jbc.M112.437970]
40. Leone TC, Lehman JJ, Finck BN, Schaeffer PJ, Wende AR, Boudina S, Courtois M, Wozniak DF, Sambandam N, Bernal-Mizrachi C, Chen Z, Holloszy JO, Medeiros DM, Schmidt RE, Saffitz JE, Abel ED, Semenkovich CF, Kelly DP. PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol 2005; 3: e101 [PMID: 15760270]
41. Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, Rhee J, Adelmant G, Stafford J, Kahn CR, Granner DK, Newgard CB, Spiegelman BM. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 2001; 413: 131-138 [PMID: 11557972]
42. Puigserver P, Rhee J, Donovan J, Walkey CJ, Yoon JC, Oriente F, Kitamura Y, Altomonte J, Dong H, Accili D, Spiegelman BM. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 2003; 423: 550-555 [PMID: 12754525]
43. Wu Y, Delerive P, Chin WW, Burris TP. Requirement of helix and the AF-2 domain of the thyroid hormone receptor for coactivation by PGC-1. J Biol Chem 2002; 277: 8898-8905 [PMID: 11751919]
44. Zhang Y, Ma K, Song S, Elam MB, Cook GA, Park EA. Peroxisomal proliferator-activated receptor-gamma coactivator-alpha (PGC-1 alpha) enhances the thyroid hormone induction of carnitine palmitoyltransferase I (CPT-I alpha). J Biol Chem 2004; 279: 53963-53971 [PMID: 15469941]
45. Sadana P, Zhang Y, Song S, Cook GA, Elam MB, Park EA. Regulation of carnitine palmitoyltransferase I (CPT-Ialpha) gene expression by the peroxisome proliferator activated receptor gamma coactivator (PGC-1) isoforms. Mol Cell Endocrinol 2007; 267: 6-16 [PMID: 17239528]
46. Attia RR, Connnaughton S, Boone LR, Wang F, Elam MB, Ness GC, Cook GA, Park EA. Regulation of pyruvate dehydrogenase kinase 4 (PDK4) by thyroid hormone: role of the peroxisome proliferator-activated receptor gamma coactivator (PGC-1 alpha). J Biol Chem 2010; 285: 2375-2385 [PMID: 19948729 DOI: 10.1074/jbc.M109.039081]
47. Gnoni GV, Rochira A, Leone A, Damiano F, Marsigliante S, Siculella L. 3,5,3'triiodo-L-thyronine induces SREBP-1 expression by non-genomic actions in human HEP G2 cells. J Cell Physiol 2012; 227: 2388-2397 [PMID: 21826653 DOI: 10.1002/jcp.22974]
48. Ness GC, Pendleton LC, Li YC, Chiang JY. Effect of thyroid hormone on hepatic cholesterol 7 alpha hydroxylase, LDL receptor, HMG-CoA reductase, farnesyl pyrophosphate synthetase and apolipoprotein A-I mRNA levels in hypophysectomized rats. Biochem Biophys Res Commun 1990; 172: 1150-1156 [PMID: 2123100]
49. Shin DJ, Osborne TF. Thyroid hormone regulation and cholesterol metabolism are connected through Sterol Regulatory Element-Binding Protein-2 (SREBP-2). J Biol Chem 2003; 278: 34114-34118 [PMID: 12829694]
50. Lopez D, Abisambra Socarrás JF, Bedi M, Ness GC. Activation of the hepatic LDL receptor promoter by thyroid hormone. Biochim Biophys Acta 2007; 1771: 1216-1225 [PMID: 17572141]
51. Pibiri M, Ledda-Columbano GM, Cossu C, Simbula G, Menegazzi M, Shinozuka H, Columbano A. Cyclin D1is an early target in hepatocyte proliferation induced by thyroid hormone (T3). FASEB J 2001; 15: 1006-1013 [PMID: 11292661]
52. Fanti M, Singh S, Ledda-Columbano GM, Columbano A, Monga SP. Triiodothyronine induces hepatocyte proliferation by protein kinase A-dependent -catenin activation in rodents. Hepatology 2013; Epub ahead of print [PMID: 24122933 DOI: 10.1002/hep.26775]
53. Meruvu S, Ayers SD, Winnier G, Webb P. Thyroid hormone analogues: where do we stand in 2013? Thyroid 2013; 23: 1333-1344 [PMID: 23915136]
54. Chiellini G, Apriletti JW, Yoshihara HA, Baxter JD, Ribeiro RC, Scanlan TS. A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor. Chem Biol 1998; 5: 299-306 [PMID: 9653548]
55. Trost SU, Swanson E, Gloss B, Wang-Iverson DB, Zhang H, Volodarsky T, Grover GJ, Baxter JD, Chiellini G, Scanlan TS, Dillmann WH. The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology 2000; 141: 3057-3064 [PMID: 10965874]
56. Miyabara EH, Aoki MS, Soares AG, Saltao RM, Vilicev CM, Passarelli M, Scanlan TS, Gouveia CH, Moriscot AS. Thyroid hormone receptor-beta-selective agonist GC-24 spares skeletal muscle type I to II fiber shift. Cell Tissue Res 2005; 321: 233-241 [PMID: 15947969]
57. Erion MD, Cable EE, Ito BR, Jiang H, Fujitaki JM, Finn PD, Zhang BH, Hou J, Boyer SH, van Poelje PD, Linemeyer DL. Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc Natl Acad Sci USA 2007; 104: 15490-15495 [PMID: 17878314]
58. Bryzgalova G, Effendic S, Khan A, Rehnmark S, Barbounis P, Boulet J, Dong G, Singh R, Shapses S, Malm J, Webb P, Baxter JD, Grover GJ. Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141. J Steroid Biochem Mol Biol 2008; 111: 262-267 [PMID: 18621127 DOI: 10.1016/j.jsbmb.2008.06.010]
59. Grover GJ, Mellström K, Malm J. Therapeutic potential for thyroid hormone receptor-beta selective agonists for treating obesity, hyperlipidemia and diabetes. Curr Vasc Pharmacol 2007; 5: 141-154 [PMID: 17430219]
60. Lin JZ, Martagón AJ, Hsueh WA, Baxter JD, Gustafsson JÅ, Webb P, Phillips KJ. Thyroid hormone receptor agonists reduce serum cholesterol independent of the LDL receptor. Endocrinology 2012; 153: 6136-6144 [PMID: 23087171 DOI: 10.1210/en.2011-2081]
61. Castillo M, Freitas BC, Rosene ML, Drigo RA, Grozovsky R, Maciel RM, Patti ME, Ribeiro MO, Bianco AC. Impaired metabolic effects of a thyroid hormone receptor betaselective agonist in a mouse model of diet-induced obesity. Thyroid 2010; 20: 545-553 [PMID: 20406106 DOI: 10.1089/ thy.2009.0318]
62. Johansson L, Rudling M, Scanlan TS, Lundåsen T, Webb P, Baxter J, Angelin B, Parini P. Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proc Natl Acad Sci USA 2005; 102: 10297-10302 [PMID: 16006512]
63. Ye L, Li YL, Mellström K, Mellin C, Bladh LG, Koehler K, Garg N, Garcia Collazo AM, Litten C, Husman B, Persson K, Ljunggren J, Grover G, Sleph PG, George R, Malm J. Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1. J Med Chem 2003; 46: 1580-1588 [PMID: 12699376]
64. Grover GJ, Mellström K, Ye L, Malm J, Li YL, Bladh LG, Sleph PG, Smith MA, George R, Vennström B, Mookhtiar K, Horvath R, Speelman J, Egan D, Baxter JD. Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc Natl Acad Sci USA 2003; 100: 10067-10072 [PMID: 12888625]
65. Baxter JD, Webb P, Grover G, Scanlan TS. Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight. Trends Endocrinol Metab 2004; 15: 154-157 [PMID: 15109613]
66. Grover GJ, Mellstrom K, Malm J. Development of the thyroid hormone receptor beta-subtype agonist KB-141: a strategy for body weight reduction and lipid lowering with minimal cardiac side effects. Cardiovasc Drug Rev 2005; 23: 133-148 [PMID: 16007230]
67. Brenta G, Danzi S, Klein I. Potential therapeutic applications of thyroid hormone analogs. Nat Clin Pract Endocrinol Metab 2007; 3: 632-640 [PMID: 17710084]
68. Berkenstam A, Kristensen J, Mellström K, Carlsson B, Malm J, Rehnmark S, Garg N, Andersson CM, Rudling M, Sjöberg F, Angelin B, Baxter JD. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc Natl Acad Sci USA 2008; 105: 663-667 [PMID: 18160532]
69. Suckling K. Selective thyromimetics for atherosclerosis and dyslipidaemia: another old target making progress. Expert Opin Investig Drugs 2008; 17: 615-618 [PMID: 18447589 DOI: 10.1517/13543784.17.5.615]
70. Tancevski I, Eller P, Patsch JR, Ritsch A. The resurgence of thyromimetics as lipid-modifying agents. Curr Opin Investig Drugs 2009; 10: 912-918 [PMID: 19705333]
71. Ladenson PW, Kristensen JD, Ridgway EC, Olsson AG, Carlsson B, Klein I, Baxter JD, Angelin B. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010; 362: 906-916 [PMID: 20220185 DOI: 10.1056/NEJMoa0905633]
72. Tancevski I, Demetz E, Eller P, Duwensee K, Hoefer J, Heim C, Stanzl U, Wehinger A, Auer K, Karer R, Huber J, Schgoer W, Van Eck M, Vanhoutte J, Fievet C, Stellaard F, Rudling M, Patsch JR, Ritsch A. The liver-selective thyromimetic T-0681 influences reverse cholesterol transport and atherosclerosis development in mice. PLoS One 2010; 5: e8722 [PMID: 20090943 DOI: 10.1371/journal.pone.0008722]
73. Tancevski I, Demetz E, Eller P. Sobetirome: a selective thyromimetic for the treatment of dyslipidemia. Recent Pat Cardiovasc Drug Discov 2011; 6: 16-19 [PMID: 21208155]
74. Grover GJ, Egan DM, Sleph PG, Beehler BC, Chiellini G, Nguyen NH, Baxter JD, Scanlan TS. Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3'-triiodo-L-thyronine. Endocrinology 2004; 145: 1656-1661 [PMID: 14701670]
75. Fujitaki JM, Cable EE, Ito BR, Zhang BH, Hou J, Yang C, Bullough DA, Ferrero JL, van Poelje PD, Linemeyer DL, Erion MD. Preclinical pharmacokinetics of a HepDirect prodrug of a novel phosphonate-containing thyroid hormone receptor agonist. Drug Metab Dispos 2008; 36: 2393-2403 [PMID: 18703645 DOI: 10.1124/dmd.108.021642]
76. Boyer SH, Jiang H, Jacintho JD, Reddy MV, Li H, Li W, Godwin JL, Schulz WG, Cable EE, Hou J, Wu R, Fujitaki JM, Hecker SJ, Erion MD. Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs. J Med Chem 2008; 51: 7075-7093 [PMID: 18975928 DOI: 10.1021/jm800824d]
77. Columbano A, Pibiri M, Deidda M, Cossu C, Scanlan TS, Chiellini G, Muntoni S, Ledda-Columbano GM. The thyroid hormone receptor-beta agonist GC-1 induces cell proliferation in rat liver and pancreas. Endocrinology 2006; 147: 3211-3218 [PMID: 16574785]
78. Villicev CM, Freitas FR, Aoki MS, Taffarel C, Scanlan TS, Moriscot AS, Ribeiro MO, Bianco AC, Gouveia CH. Thyroid hormone receptor beta-specific agonist GC-1 increases energy expenditure and prevents fat-mass accumulation inrats. J Endocrinol 2007; 193: 21-29 [PMID: 17400799]
79. Venditti P, Chiellini G, Di Stefano L, Napolitano G, Zucchi R, Columbano A, Scanlan TS, Di Meo S. The TRbetaselective agonist, GC-1, stimulates mitochondrial oxidative processes to a lesser extent than triiodothyronine. J Endocrinol 2010; 205: 279-289 [PMID: 20360308 DOI: 10.1677/ JOE-10-0036]
80. Cioffi F, Lanni A, Goglia F. Thyroid hormones, mitochondrial bioenergetics and lipid handling. Curr Opin Endocrinol Diabetes Obes 2010; 17: 402-407 [PMID: 20625286 DOI: 10.1097/MED.0b013e32833cf354]
81. Lin VW, Klepp HM, Hanley RM. Sobetirome is a TRβ-and liver-selective thyromimetic that can effect substantial LDL-C lowering without significant changes in heart rate or the thyroid axis in euthyroid men. 90th Annual Meeting of The Endocrine Society; 2008 June 15-18; San Francisco, California, USA. The Endocrine Society, 2008: OR36-33
82. Tancevski I, Rudling M, Eller P. Thyromimetics: a journey from bench to bed-side. Pharmacol Ther 2011; 131: 33-39 [PMID: 21504761 DOI: 10.1016/j.pharmthera.2011.04.003]
83. Cable EE, Finn PD, Stebbins JW, Hou J, Ito BR, van Poelje PD, Linemeyer DL, Erion MD. Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist. Hepatology 2009; 49: 407-417 [PMID: 19072834 DOI: 10.1002/hep.22572]
84. Ito BR, Zhang BH, Cable EE, Song X, Fujitaki JM, MacKenna DA, Wilker CE, Chi B, van Poelje PD, Linemeyer DL, Erion MD. Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys. Br J Pharmacol 2009; 156: 454-465 [PMID: 19183199 DOI: 10.1111/ j.1750-3639.2009.00038.x]
85. Moreno M, Lombardi A, Beneduce L, Silvestri E, Pinna G, Goglia F, Lanni A. Are the effects of T3 on resting metabolic rate in euthyroid rats entirely caused by T3 itself? Endocrinology 2002; 143: 504-510 [PMID: 11796504]
86. Pinna G, Hiedra L, Meinhold H, Eravci M, Prengel H, Brödel O, Gräf KJ, Stoltenburg-Didinger G, Bauer M, Baumgartner A. 3,3'-Diiodothyronine concentrations in the sera of patients with nonthyroidal illnesses and brain tumors and of healthy subjects during acute stress. J Clin Endocrinol Metab 1998; 83: 3071-3077 [PMID: 9745405]
87. Murthy JN, Yatscoff RW, Soldin SJ. Cyclosporine metabolite cross-reactivity in different cyclosporine assays. Clin Biochem 1998; 31: 159-163 [PMID: 9629489]
88. Soldin SJ, Steele BW, Witte DL, Wang E, Elin RJ. Lack of specificity of cyclosporine immunoassays. Results of a College of American Pathologists Study. Arch Pathol Lab Med 2003; 127: 19-22 [PMID: 12521361]
89. Hopley CJ, Stokes P, Webb KS, Baynham M. The analysis of thyroxine in human serum by an 'exact matching' isotope dilution method with liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2004; 18: 1033-1038 [PMID: 15150825]
90. Van Uytfanghe K, Stöckl D, Thienpont LM. Development of a simplified sample pretreatment procedure as part of an isotope dilution-liquid chromatography/tandem mass spectrometry candidate reference measurement procedure for serum total thyroxine. Rapid Commun Mass Spectrom 2004; 18: 1539-1540 [PMID: 15216518]
91. Soukhova N, Soldin OP, Soldin SJ. Isotope dilution tandem mass spectrometric method for T4/T3. Clin Chim Acta 2004; 343: 185-190 [PMID: 15115693]
92. Tai SS, Bunk DM, White E, Welch MJ. Development and evaluation of a reference measurement procedure for the determination of total 3,3',5-triiodothyronine in human serum using isotope-dilution liquid chromatography-tandem mass spectrometry. Anal Chem 2004; 76: 5092-5096 [PMID: 15373447]
93. Hantson AL, De Meyer M, Guérit N. Simultaneous determination of endogenous and 13C-labelled thyroid hormones in plasma by stable isotope dilution mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 807: 185-192 [PMID: 15203028]
94. Zhang Y, Conrad AH, Conrad GW. Detection and quantification of 3,5,3'-triiodothyronine and 3,3',5'-triiodothyronine by electrospray ionization tandem mass spectrometry. J Am Soc Mass Spectrom 2005; 16: 1781-1786 [PMID: 16182556]
95. Zhang Y, Conrad AH, Thoma R, Conrad GW. Differentiation of diiodothyronines using electrospray ionization tandem mass spectrometry. J Mass Spectrom 2006; 41: 162-168 [PMID: 16353128]
96. Köhrle J, Martin C, Renko K, Hoefig CS. Simultaneous analysis of all nine possible iodothyronines by liquid chromatography-tandem mass spectrometry. In: Smit J, Visser T, editors. 37th Annual Meeting of European Thyroid Association; 2013 Sep 7-11; Leiden, The Netherlands. Basel, Reinhhardt Druck: Karger, 2013: P241 p.176
97. Lehmphul I, Wu Z, Strasburger CJ, Köhrle J. Establishment of a competitive chemiluminescence immunoassay to detect 3,5-diiodo-L-thyronine in human serum. In: Smit J, Visser T, editors. 37th Annual Meeting of European Thyroid Association; 2013 Sep 7-11; Leiden, The Netherlands. Basel, Reinhhardt Druck: Karger, 2013: P246 p.178
98. Ball SG, Sokolov J, Chin WW. 3,5-Diiodo-L-thyronine (T2) has selective thyromimetic effects in vivo and in vitro. J Mol Endocrinol 1997; 19: 137-147 [PMID: 9343306]
99. Mendoza A, Navarrete-Ramírez P, Hernández-Puga G, Villalobos P, Holzer G, Renaud JP, Laudet V, Orozco A. 3,5-T2 is an alternative ligand for the thyroid hormone receptor β1. Endocrinology 2013; 154: 2948-2958 [PMID: 23736295 DOI: 10.1210/en.2013-1030]
100. Navarrete-Ramírez P, Luna M, Valverde-R C, Orozco A. 3,5-di-iodothyronine stimulates tilapia growth through an alternate isoform of thyroid hormone receptor β1. J Mol Endocrinol 2014; 52: 1-9 [PMID: 24031088]
101. Lanni A, Moreno M, Cioffi M, Goglia F. Effect of 3,3'-diiodothyronine and 3,5-diiodothyronine on rat liver oxidative capacity. Mol Cell Endocrinol 1992; 86: 143-148 [PMID: 1324858]
102. Lanni A, Moreno M, Cioffi M, Goglia F. Effect of 3,3'-diiodothyronine and 3,5-di-iodothyronine on rat liver mitochondria. J Endocrinol 1993; 136: 59-64 [PMID: 8381457]
103. Lanni A, Moreno M, Lombardi A, Goglia F. Rapid stimulation in vitro of rat liver cytochrome oxidase activity by 3,5-diiodo-L-thyronine and by 3,3'-diiodo-L-thyronine. Mol Cell Endocrinol 1994; 99: 89-94 [PMID: 8187965]
104. Arnold S, Goglia F, Kadenbach B. 3,5-Diiodothyronine binds to subunit Va of cytochrome-c oxidase and abolishes the allosteric inhibition of respiration by ATP. Eur J Biochem 1998; 252: 325-330 [PMID: 9523704]
105. Kadenbach B, Hüttemann M, Arnold S, Lee I, Bender E. Mitochondrial energy metabolism is regulated via nuclearcoded subunits of cytochrome c oxidase. Free Radic Biol Med 2000; 29: 211-221 [PMID: 11035249]
106. Scapin S, Leoni S, Spagnuolo S, Gnocchi D, De Vito P, Luly P, Pedersen JZ, Incerpi S. Short-term effects of thyroid hormones during development: Focus on signal transduction. Steroids 2010; 75: 576-584 [PMID: 19900468 DOI: 10.1016/ j.steroids.2009.10.013]
107. Grasselli E, Voci A, Canesi L, De Matteis R, Goglia F, Cioffi F, Fugassa E, Gallo G, Vergani L. Direct effects of iodothyronines on excess fat storage in rat hepatocytes. J Hepatol 2011; 54: 1230-1236 [PMID: 21145833 DOI: 10.1016/ j.jhep.2010.09.027]
108. Grasselli E, Voci A, Demori I, Canesi L, De Matteis R, Goglia F, Lanni A, Gallo G, Vergani L. 3,5-Diiodo-L-thyronine modulates the expression of genes of lipid metabolismin a rat model of fatty liver. J Endocrinol 2012; 212: 149-158 [PMID: 22107956 DOI: 10.1530/JOE-11-0288]
109. Goglia F, Moreno M, Lanni A. Action of thyroid hormones at the cellular level: the mitochondrial target. FEBS Lett 1999; 452: 115-120 [PMID: 10386574]
110. Antonelli A, Fallahi P, Ferrari SM, Di Domenicantonio A, Moreno M, Lanni A, Goglia F. 3,5-diiodo-L-thyronine increases resting metabolic rate and reduces body weight without undesirable side effects. J Biol Regul Homeost Agents 2011; 25: 655-660 [PMID: 22217997]
111. Lanni A, Moreno M, Lombardi A, de Lange P, Silvestri E, Ragni M, Farina P, Baccari GC, Fallahi P, Antonelli A, Goglia F. 3,5-diiodo-L-thyronine powerfully reduces adiposity in rats by increasing the burning of fats. FASEB J 2005; 19: 1552-1554 [PMID: 16014396]
112. Mollica MP, Lionetti L, Moreno M, Lombardi A, De Lange P, Antonelli A, Lanni A, Cavaliere G, Barletta A, Goglia F. 3,5-diiodo-l-thyronine, by modulating mitochondrial functions, reverses hepatic fat accumulation in rats fed a highfat diet. J Hepatol 2009; 51: 363-370 [PMID: 19464748 DOI: 10.1016/j.jhep.2009.03.023]
113. Silvestri E, Cioffi F, Glinni D, Ceccarelli M, Lombardi A, de Lange P, Chambery A, Severino V, Lanni A, Goglia F, Moreno M. Pathways affected by 3,5-diiodo-l-thyronine in liver of high fat-fed rats: evidence from two-dimensional electrophoresis, blue-native PAGE, and mass spectrometry. Mol Biosyst 2010; 6: 2256-2271 [PMID: 20844788 DOI: 10.1039/c0mb00040j]
114. de Lange P, Cioffi F, Senese R, Moreno M, Lombardi A, Silvestri E, De Matteis R, Lionetti L, Mollica MP, Goglia F, Lanni A. Nonthyrotoxic prevention of diet-induced insulin resistance by 3,5-diiodo-L-thyronine in rats. Diabetes 2011; 60: 2730-2739 [PMID: 21926273 DOI: 10.2337/db11-0207]
115. Moreno M, Lombardi A, De Lange P, Silvestri E, Ragni M, Lanni A, Goglia F. Fasting, lipid metabolism, and triiodothyronine in rat gastrocnemius muscle: interrelated roles of uncoupling protein 3, mitochondrial thioesterase, and coenzyme Q. FASEB J 2003; 17: 1112-1114 [PMID: 12692085]
116. de Lange P, Ragni M, Silvestri E, Moreno M, Schiavo L, Lombardi A, Farina P, Feola A, Goglia F, Lanni A. Combined cDNA array/RT-PCR analysis of gene expression profile in rat gastrocnemius muscle: relation to its adaptive function in energy metabolism during fasting. FASEB J 2004; 18: 350-352 [PMID: 14656997]
117. de Lange P, Farina P, Moreno M, Ragni M, Lombardi A, Silvestri E, Burrone L, Lanni A, Goglia F. Sequential changes in the signal transduction responses of skeletal muscle following food deprivation. FASEB J 2006; 20: 2579-2581 [PMID: 17065218]
118. de Lange P, Moreno M, Silvestri E, Lombardi A, Goglia F, Lanni A. Fuel economy in food-deprived skeletal muscle: signaling pathways and regulatory mechanisms. FASEB J 2007; 21: 3431-3441 [PMID: 17595346]
119. Moreno M, Silvestri E, De Matteis R, de Lange P, Lombardi A, Glinni D, Senese R, Cioffi F, Salzano AM, Scaloni A, Lanni A, Goglia F. 3,5-Diiodo-L-thyronine prevents highfat-diet-induced insulin resistance in rat skeletal muscle through metabolic and structural adaptations. FASEB J 2011; 25: 3312-3324 [PMID: 21670063 DOI: 10.1096/fj.11-181982]
120. Goldberg IJ, Huang LS, Huggins LA, Yu S, Nagareddy PR, Scanlan TS, Ehrenkranz JR. Thyroid hormone reduces cholesterol via a non-LDL receptor-mediated pathway. Endocrinology 2012; 153: 5143-5149 [PMID: 22948212 DOI: 10.1210/en.2012-1572]
121. Grasselli E, Canesi L, Voci A, De Matteis R, Demori I, Fugassa E, Vergani L. Effects of 3,5-diiodo-L-thyronine administration on the liver of high fat diet-fed rats. Exp Biol Med (Maywood) 2008; 233: 549-557 [PMID: 18375830 DOI: 10.3181/0710-RM-266]
122. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, Machado De Oliveira R, Leid M, McBurney MW, Guarente L. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004; 429: 771-776 [PMID: 15175761]
123. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005; 434: 113-118 [PMID: 15744310]
124. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444: 337-342 [PMID: 17086191]
125. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006; 127: 1109-1122 [PMID: 17112576]
126. Gerhart-Hines Z, Rodgers JT, Bare O, Lerin C, Kim SH, Mostoslavsky R, Alt FW, Wu Z, Puigserver P. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J 2007; 26: 1913-1923 [PMID: 17347648]
127. Feige JN, Lagouge M, Canto C, Strehle A, Houten SM, Milne JC, Lambert PD, Mataki C, Elliott PJ, Auwerx J. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab 2008; 8: 347-358 [PMID: 19046567 DOI: 10.1016/j.cmet.2008.08.017]
128. Grasselli E, Voci A, Canesi L, Goglia F, Ravera S, Panfoli I, Gallo G, Vergani L. Non-receptor-mediated actions are responsible for the lipid-lowering effects of iodothyronines in FaO rat hepatoma cells. J Endocrinol 2011; 210: 59-69 [PMID: 21508094 DOI: 10.1530/JOE-11-0074]
129. Cioffi F, Zambad SP, Chhipa L, Senese R, Busiello RA, Tuli D, Munshi S, Moreno M, Lombardi A, Gupta RC, Chauthaiwale V, Dutt C, de Lange P, Silvestri E, Lanni A, Goglia F. TRC150094, a novel functional analog of iodothyronines, reduces adiposity by increasing energy expenditure and fatty acid oxidation in rats receiving a high-fat diet. FASEB J 2010; 24: 3451-3461 [PMID: 20453112 DOI: 10.1096/fj.10-157115]
130. Silvestri E, Glinni D, Cioffi F, Moreno M, Lombardi A, de Lange P, Senese R, Ceccarelli M, Salzano AM, Scaloni A, Lanni A, Goglia F. Metabolic effects of the iodothyronine functional analogue TRC150094 on the liver and skeletal muscle of high-fat diet fed overweight rats: an integrated proteomic study. Mol Biosyst 2012; 8: 1987-2000 [PMID: 22543897 DOI: 10.1039/c2mb25055a]
131. Zambad SP, Munshi S, Dubey A, Gupta R, Busiello RA, Lanni A, Goglia F, Gupta RC, Chauthaiwale V, Dutt C. TRC150094 attenuates progression of nontraditional cardiovascular risk factors associated with obesity and type 2 diabetes in obese ZSF1 rats. Diabetes Metab Syndr Obes 2011; 4: 5-16 [PMID: 21448317 DOI: 10.2147/DMSOTT.S15323]
132. Grattagliano I, de Bari O, Bernardo TC, Oliveira PJ, Wang DQ, Portincasa P. Role of mitochondria in nonalcoholic fatty liver disease--from origin to propagation. Clin Biochem 2012; 45: 610-618 [PMID: 22484459 DOI: 10.1016/j.clinbiochem.20 12.03.024]
133. Cioffi F, Senese R, Lanni A, Goglia F. Thyroid hormones and mitochondria: with a brief look at derivatives and analogues. Mol Cell Endocrinol 2013; 379: 51-61 [PMID: 23769708 DOI: 10.1016/j.mce.2013.06.006]
134. Goglia F, Torresani J, Bugli P, Barletta A, Liverini G. Invitro binding of triiodothyronine to rat liver mitochondria. Pflugers Arch 1981; 390: 120-124 [PMID: 7195560]
135. Wrutniak-Cabello C, Casas F, Cabello G. Thyroid hormone action in mitochondria. J Mol Endocrinol 2001; 26: 67-77 [PMID: 11174855]
136. Psarra AM, Solakidi S, Sekeris CE. The mitochondrion as a primary site of action of steroid and thyroid hormones: presence and action of steroid and thyroid hormone receptors in mitochondria of animal cells. Mol Cell Endocrinol 2006; 246: 21-33 [PMID: 16388892]
137. Gaspari M, Larsson NG, Gustafsson CM. The transcription machinery in mammalian mitochondria. Biochim Biophys Acta 2004; 1659: 148-152 [PMID: 15576046]
138. Scarpulla RC. Nuclear control of respiratory gene expression in mammalian cells. J Cell Biochem 2006; 97: 673-683 [PMID: 16329141]